| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Ganoderic acid Y targets multiple pathways. It acts as an α-glucosidase inhibitor, with an IC50 of 170 μM for yeast α-glucosidase. By inhibiting α-glucosidase, it may modulate carbohydrate metabolism. The compound inhibits the replication of enterovirus 71 (EV71) by preventing its uncoating. It also exhibits anti-inflammatory, anticancer, and antioxidant activities. Its multiple targets make it a valuable research tool for studying various diseases.
|
|---|---|
| ln Vitro |
Significantly, EV71 viral RNA (vRNA) replication is inhibited by ganoderic acid Y [2].
In vitro, ganoderic acid Y is an α-glucosidase inhibitor with an IC50 of 170 μM for yeast α-glucosidase. It inhibits the replication of enterovirus 71 (EV71) by preventing its uncoating. EV71 viral RNA replication is significantly inhibited by ganoderic acid Y. The compound exhibits anti-inflammatory, anticancer, and antioxidant activities. Its activity is typically evaluated using enzyme inhibition assays, antiviral assays, and cell-based assays measuring cell viability and inflammatory markers. |
| ln Vivo |
In vivo, ganoderic acid Y has been studied for its antiviral, anti-inflammatory, and anticancer effects. As an inhibitor of EV71 replication, it has potential for treating enterovirus infections. Its α-glucosidase inhibitory activity suggests potential applications in diabetes management. The compound's anti-inflammatory and antioxidant activities may contribute to its therapeutic potential in various diseases. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature.
|
| Enzyme Assay |
Cell-free assays for ganoderic acid Y involve measuring its α-glucosidase inhibitory activity. Yeast α-glucosidase is incubated with varying concentrations of ganoderic acid Y and a substrate such as p-nitrophenyl-α-D-glucopyranoside. The IC50 value of 170 μM is determined from dose-response curves. Antiviral activity can be assessed using biochemical assays targeting EV71 uncoating. The compound's chemical purity and identity are confirmed by HPLC, NMR, and mass spectrometry.
|
| Cell Assay |
In vitro cellular assays for ganoderic acid Y typically involve treating EV71-infected cells with the compound. Cells are incubated with various concentrations of ganoderic acid Y, and viral replication is assessed by measuring viral RNA levels. Antiviral efficacy is evaluated by comparing viral titers between treated and untreated cells. Cytotoxicity is assessed using standard cell viability assays. Anti-inflammatory activity is evaluated in macrophage cell lines by measuring cytokine production.
|
| Animal Protocol |
In vivo animal studies for ganoderic acid Y are conducted in models of enterovirus infection, diabetes, and inflammation. The compound is administered via various routes including oral gavage or intraperitoneal injection. Viral titers in tissues are measured in infection models. Blood glucose levels are monitored in diabetes models. Inflammatory markers in serum and tissues are assessed. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ganoderic acid Y include a molecular weight of 454.68 g/mol, molecular formula C30H46O3, and purity ≥98%. It has a LogP of 7.319. The compound requires protection from light during transportation and storage. It is stable as a powder at -20°C for 3 years or at 4°C for 2 years. In solvent, it is stable at -80°C for 6 months or at -20°C for 1 month. Detailed ADME parameters are not extensively reported.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ganoderic acid Y has not been extensively characterized in published literature. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have a favorable safety profile at research doses. The compound shows good antiviral effects in vitro. Standard safety precautions should be followed when handling this compound. It is intended for research use only and not for therapeutic applications in humans.
|
| References |
|
| Additional Infomation |
Lanostacid Y is a triterpenoid compound. It has been reported that Lanosta-7,9(11),24-trien-26-acid, 3-hydroxy-,(3β,24E)- has been found in Ganoderma lucidum, Ganoderma sylvestris, and Ganoderma brevicornu, and related data are available.
Ganoderic acid Y is a triterpenoid from Ganoderma lucidum that acts as an α-glucosidase inhibitor (IC50 = 170 μM). It inhibits EV71 replication by preventing viral uncoating. The compound exhibits anti-inflammatory, anticancer, and antioxidant activities. Its molecular formula is C30H46O3 with a molecular weight of 454.68 g/mol. Ganoderic acid Y is a research tool for studying viral infections, diabetes, and inflammation. |
| Molecular Formula |
C30H46O3
|
|---|---|
| Molecular Weight |
454.6844
|
| Exact Mass |
454.345
|
| CAS # |
86377-52-8
|
| PubChem CID |
57397445
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.319
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
908
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CC/C=C(\C)/C(=O)O)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
|
| InChi Key |
HUTCYUJPLOTDMX-SPPZYOJVSA-N
|
| InChi Code |
InChI=1S/C30H46O3/c1-19(9-8-10-20(2)26(32)33)21-13-17-30(7)23-11-12-24-27(3,4)25(31)15-16-28(24,5)22(23)14-18-29(21,30)6/h10-11,14,19,21,24-25,31H,8-9,12-13,15-18H2,1-7H3,(H,32,33)/b20-10+/t19-,21-,24+,25+,28-,29-,30+/m1/s1
|
| Chemical Name |
(E,6R)-6-[(3S,5R,10S,13R,14R,17R)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1993 mL | 10.9967 mL | 21.9935 mL | |
| 5 mM | 0.4399 mL | 2.1993 mL | 4.3987 mL | |
| 10 mM | 0.2199 mL | 1.0997 mL | 2.1993 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
